ONTAK (denileukin difitox, DAB389IL-2)
ApprovedCompleted 0 watching 0 views this week🔥 Hot
85
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Lymphoma, T-Cell, Cutaneous
Conditions
Lymphoma, T-Cell, Cutaneous
Trial Timeline
May 1, 2001 → Jan 1, 2006
NCT ID
NCT00211198About ONTAK (denileukin difitox, DAB389IL-2)
ONTAK (denileukin difitox, DAB389IL-2) is a approved stage product being developed by Eisai for Lymphoma, T-Cell, Cutaneous. The current trial status is completed. This product is registered under clinical trial identifier NCT00211198. Target conditions include Lymphoma, T-Cell, Cutaneous.
Hype Score Breakdown
Clinical
30
Activity
20
Company
10
Novelty
10
Community
12
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00211198 | Approved | Completed |
Competing Products
20 competing products in Lymphoma, T-Cell, Cutaneous